联合检测血清EMAb及CA-125在子宫内膜异位症中的应用

Determination of sera EMAb and CA125 in patients with endometriosis

分别采用酶联免疫吸附法（ＥＬＩＳＡ）及放射免疫法测定了１５９ 例子宫内膜异位症（内异症）患者（内异症组）血清子宫内膜抗体（ＥＭＡｂ）及卵巢上皮癌相关抗原（ＣＡ－１２５）水平，并与正常对照组比较。结果：治疗前内异症组ＥＭＡｂ 及ＣＡ－１２５ 阳性率均明显高于对照组，Ｐ均＜ ０．０５。单独测定ＥＭＡｂ诊断内异症的敏感性为６４．１５％ ，特异性为９２．５０％ ；单独测定ＣＡ－１２５ 的敏感性为８１．１３％ ，特异性为９７．５０％ 。如以ＥＭＡｂ 及ＣＡ－１２５ 均阳性为诊断标准，则诊断内异症的敏感性为５４．００％ ，特异性为１００％ 。治疗后１、３ 个月复查，ＥＭＡｂ 及ＣＡ－１２５ 阳性率均明显降低。认为测定血清ＥＭＡｂ、ＣＡ－１２５ 是目前较好的无创伤性诊断内异症的辅助方法，亦有助于内异症的疗效判定，联合测定ＥＭＡｂ 及ＣＡ－１２５，则更能提高诊断价值。

The sera endometriosis antibody(EMAb) and CA125 of 159 patients with endometriosis(EMs group) and 40 healthy women (control group)were determinated by enzyme linked immunosorbent assay(ELISA)and radioimmunoassay (RIA).Results showed that the positive rate of EMAb was 64.15% in EMS group before treatment, 7.50% in control group,the difference in two groups was significant (P<0.05).The positive rate of CA125 was 81.3% in EMs group,2.50% in control group,the difference in two groups also significant(P<0.05).If determining EMAb alone,the sensitivity rate of diagnosis EMs was 64.15% the specificity rate was 92.50%.If determining CA125 alone,the above rates were 81.13%,97.50% respectively.If EMAb and CA125 were both positive,the above rates were 54.00% and 100%. If one of them was positive,the above rate were 91.19% and 90.00%.The positive rates of EMAb and CA125 were decreased siganificantly after treatment.The results suggest that the determination of serum EMAb or CA125 is helpful for the diagnosis of EMs and evaluation of curative effect. If combinig use of EMAb and CA125,the value of diagnosis is better.